HOME >> BIOLOGY >> NEWS
Potent new compound from blue-green algae may help treat, elucidate nerve disorders

Click here for abstract.

HONOLULU, Dec. 19 - Amid a growing list of biologically useful chemicals from the sea, a newly discovered compound - kalkitoxin - stands out for its potential to help researchers understand nerve function, which could someday lead to new treatments for pain, epilepsy and possibly stroke. The finding was reported here today at the 2000 International Chemical Congress of Pacific Basin Societies.

The weeklong scientific meeting, held once every five years, is hosted by the American Chemical Society, in conjunction with its counterparts in Australia, Canada, Japan and New Zealand.

Lead investigator William Gerwick, Ph.D., a pharmacy professor at Oregon State University in Corvallis, says the neurotoxin - a metabolite in cyanobacteria - is fundamentally new in both structure and potency.

"What we've found is a spectacularly potent neurotoxin, meaning kalkitoxin can kill neurons," explained Gerwick. "And when a compound is very toxic, it's working by a very specific mechanism." He and his collaborators hope to use that mechanism "to dissect neurochemical pathways and to understand how drugs affect them," he said.

Their discovery began "in an absolutely beautiful bay" of the Caribbean island of Curacao, near Venezuela, Gerwick said. "In 1994, we found a collection of cyanobacteria growing like hairs off the sea floor. We brought several liters of it back to Oregon for testing." Marine cyanobacteria, also called blue-green algae, are most familiar to many people as "pond scum."

Back in the laboratory, Gerwick's team ground up samples of the simple plant and tested extracts on brine shrimp and fish. One extract proved toxic even in concentrations of parts per billion. The researchers named the as-yet-mysterious compound after the island's Kalki Bay
'"/>

Contact: Charmayne Marsh
y_marsh@acs.org
808-944-6381
American Chemical Society
18-Dec-2000


Page: 1 2

Related biology news :

1. Potential for enhanced sequestration of carbon in soils supports evaluations
2. Potent toxin reveals new antibiotic resistance mechanism
3. Potential blood test for colon cancer risk
4. Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute
5. Potential cause of arthritis discovered
6. Potential of regenerative medicine explored
7. Potential therapy reported for children, adults with end-stage liver disease
8. Potential allergy vaccine boosts hope for sufferers
9. Potential of tailoring drugs to genetic makeup confirmed--but challenges remain
10. Potential new anthrax therapy discovered
11. Potential gene therapy carriers created that mimic viruses, without the risk

Post Your Comments:
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE ... collaboration catalyst that provides the connective tissue that enhances ... enabling them to easily share client-level information; earned a ... to expand to organizations serving seniors aging in community ... Diego" partner on December 11 th 4-6p. ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Strict ... driver efficiency are piloting the North American and European ... of accidents growing, gesture recognition systems that are intuitive ... a mark in the industry. New ... Automotive Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
(Date:12/17/2014)... Bellingham, Washington, USA (PRWEB) December 16, 2014 ... Kirstin Baum, manager at Philipps- Universität Marburg’s Department ... optics and photonics, in the newly released ... 2015-2016. “And never be too shy to ask ... STEM (science, technology, engineering, and mathematics) occupations ranging ...
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
(Date:12/17/2014)... Dallas, Texas (PRWEB) December 17, 2014 ... research on Global Quartz Tubing industry. For an ... information, definition, classification, application, industry chain structure, industry ... domestic quartz tubing industry has witnessed ... through a number of acquisitions. This report mentions ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 ... today that it has entered into a technology ... Company (ADM) to apply DNA2.0’s proprietary protein engineering ... engineering process. , “We are extremely excited that ... engineering platform. This proprietary bioengineering technology has ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
Cached News: